[Trials of monosialoganglioside (Sygen) treatment in ischemic stroke].
65 patients with ischaemic stroke were treated for 6 weeks by intramuscular injections of Sygen--monosialoganglioside 40 mg daily. The results were double-blinded and compared with those in placebo group (Vitamin PP). The results evaluated by Mathew scale did not show any significant differences between both groups. However in the Sygen group we have noticed more patients with very good therapeutic results (almost complete recovery of functions). Immunological studies have not revealed any reaction, which may be considered as a result of allergogenic action of monosialoganglioside.
Wender
M
M
Katedry i Kliniki Neurologii AM, Poznaniu.
Mularek
J
J
Godlewski
A
A
Losy
J
J
Michałowska-Wender
G
G
Sniatała-Kamasa
M
M
Wójcicka
M
M
D000328:Adult; D000368:Aged; D001921:Brain / Q000098:blood supply / Q000503:physiopathology; D001927:Brain Diseases / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D005677:G(M1) Ganglioside / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010919:Placebos
D007074:Immunoglobulin G; D010919:Placebos; D005677:G(M1) Ganglioside
Próby leczenia monosialogangliozydem (Sygenem) chorych z niedokrwiennym udarem mózgu.